Fig. 6: Efficacy of ERBB2-directed ADC treatment.
a Treatment history of patient DSRCT-28, illustrating 18-month disease control with T-DXd. Details of the individual therapies are provided in Supplementary Table 7. b ERBB2 mRNA expression, determined by RNA-seq, in tumor tissue from patient DSRCT-28. The transcript-per-million (TPM) value of patient DSRCT-28 is indicated by a blue circle, showing its relative position within the cohort (n = 26). c ERBB2 protein expression, determined by IHC, in tumor tissue from patient DSRCT-28. d Assessment of T-DXd response by positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG-PET/CT) in patient DSRCT-28. The maximum intensity projections of metabolically visible tumor manifestations over time are shown. e Treatment history of patient DSRCT-30, illustrating 24-month disease control with T-DXd. The details of the individual therapies are shown in Supplementary Table 9. f ERBB2 mRNA expression, determined by RNA-seq, in tumor tissue from patient DSRCT-30. The TPM value of patient DSRCT-30 is indicated by a blue circle, showing its relative position within the cohort (n = 26). g ERBB2 protein expression, determined by IHC, in tumor tissue from patient DSRCT-30. h Assessment of T-DXd response using 18F-FDG-PET/CT in patient DSRCT-30. The maximum intensity projections of metabolically visible tumor manifestations over time are shown. Scale bars, 20 µm. MPR, metabolic partial response; MSD, metabolic stable disease; MTV, metabolic tumor volume; SUV, standard uptake value; TLG, tumor lesion glycolysis. Source data for (b, c, f, g) are provided in the Source Data file.
